

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/139108 A1

(51) International Patent Classification:

A61K 31/5575 (2006.01) *A61P 11/00* (2006.01)
A61K 9/00 (2006.01) *A61M 11/00* (2006.01)
A61K 9/08 (2006.01)

(72) Inventors: **D'OREY MARCHAND SEQUEIRA LOPES**

BEIRÃO BELO, Isabel; Rua Afonso de Albuquerque 9,
2780-307 Oeiras (PT). **RAWERT, Jürgen**; Im Rapsfeld
30c, 50933 Köln (DE).

(21) International Application Number:

PCT/EP2023/051102

(74) Agent: **PHARMA PATENTS INTERNATIONAL AG**;

Leonhardsgraben 52, 4051 Basel (CH).

(22) International Filing Date:

18 January 2023 (18.01.2023)

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(25) Filing Language:

English

(26) Publication Language:


English

(30) Priority Data:

22152809.4 21 January 2022 (21.01.2022) EP

(71) Applicant: **SOFTHALE NV** [BE/BE]; Agoralaan Build-
ing Abis, 3590 Diepenbeek (BE).

(54) Title: TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION



(57) **Abstract:** The invention provides Treprostinil or a pharmaceutically acceptable salt or derivative thereof for use in a method of treatment of pulmonary hypertension in a subject being diagnosed with pulmonary hypertension or being at risk of developing pulmonary hypertension wherein the treatment comprises the steps of i) administering to said subject a first liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a first concentration in aerosolized form for a first treatment period, and ii) administering to said subject a second liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a second concentration in aerosolized form for a second treatment period following the first treatment period; wherein the second concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the second liquid composition is higher than the first concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the first

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

liquid composition, and wherein the first and the second liquid compositions are aerosolized and administered to the subject using a soft mist inhaler.